GlassScriptPhysician profile
Pear Enam
NPI 1780687616
$46,021.90
in general payments reported to CMS, 2019-2025
9 companies · $45K in 2025
The $45K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.54 · 2020: $87.55 · 2021: $45.00 · 2022: $58.74 · 2023: $78.78 · 2024: $519 · 2025: $45K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $45K · Food and Beverage: $581 · Education: $17.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $45,221.33 |
| Food and Beverage | $580.50 |
| Education | $17.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Capsovision, INC. | $45,221.33 | 2025 | Capsocam Plus, Capsocam Colon |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $294.90 | 2019-2024 | Xifaxan, Plenvu, Trulance |
| Phathom Pharmaceuticals, INC. | $196.16 | 2023-2024 | Voquezna |
| Abbvie INC. | $126.80 | 2021-2024 | |
| Janssen Biotech, INC. | $107.49 | 2024 | Stelara |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.37 | 2024 | Cyltezo |
| Celltrion USA INC. | $17.24 | 2024 | Zymfentra |
| Braintree Laboratories, INC. | $15.31 | 2023 | Suflave, Sutab |
| Medtronic, INC. | $14.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pear Enam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.